Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)

SAN BRUNO, Calif. and LOS ANGELES, April 26, 2018 -- (Healthcare Sales & Marketing Network) -- Neuraltus Pharmaceuticals, Inc., a privately-held pharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, today a... Biopharmaceuticals, Neurology Neuraltus Pharmaceuticals, Amyotrophic Lateral Sclerosis

Source: HSMN NewsFeed - April 26, 2018 Category: Pharmaceuticals Source Type: news